Bill > S797

This bill directs the Health Policy Commission to conduct a study examining the feasibility of establishing a state-run program to manufacture generic or biosimilar prescription drugs. The study will analyze whether such a program would increase competition, lower drug prices, address shortages, and improve patient access to affordable medications in Massachusetts. The Commission will examine factors contributing to high drug costs, the impact of generic drug costs on MassHealth and the broader healthcare system, and the potential benefits of a state-directed manufacturing program. The Commission will submit a report with its findings and recommendations, including a cost-benefit analysis and a plan for implementing such a program if deemed effective.

Health and Social Services

https://malegislature.gov/Bills/193/S797